AMYT Amryt Pharma PLC

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Amryt Pharma (AMYT - Research Report), with a price target of $18.00. The company's shares opened today at $7.00.Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, Vertex Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Rahman has an average return of -38.1% and a 16.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amryt Pharma with a $18.33 average price target, implying a 161.86% upside from current levels. In a report released today, H.C.
https://www.tipranks.com/news/blurbs/amryt-pharma-amyt-receives-a-buy-from-maxim-group-2?utm_source=advfn.com&utm_medium=referral